Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleai

Full company profile

uuid000083g

Namestring
Nucleai
Legal namestring
Nucleai Ltd.
Websiteurl
nucleai.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Nucleai is a spatial biology company founded in 2017/2018 in Israel by Avi Veidman, applying geospatial and satellite-imagery AI techniques to the analysis of tissue biopsies. The company has built an AI-powered multimodal spatial biology platform that ingests H&E, IHC, multiplex immunofluorescence (mIF), and spatial transcriptomics images to perform spatial biomarker discovery, scoring, and prediction of therapy response. The platform is delivered as a cloud application (app.nucleai.cloud) and includes specialized deep-learning models — including a high-plex imaging normalization model with reported 20x speedup and an LLM-based spatial proteomics agent that generates automated reports — supported by peer-reviewed publications in Nature Communications and Modern Pathology.

Nucleai's customer base is concentrated in the top tier of biopharmaceutical companies, with stated engagement with 20+ pharma customers including Gilead, Amgen, and other Top 20 Biopharma. Revenue is generated through three primary streams: enterprise SaaS and platform licensing to biopharma, strategic co-development arrangements with CROs (Sirona Dx) and life-science tools companies (Bio-Techne/Lunaphore), and research-use-only image analysis services for academic and translational research. The company operates a dual-headquarters structure with offices in Tel Aviv, Israel (R&D and engineering) and Chicago, Illinois (US commercial operations).

Total disclosed equity funding is approximately $60M, raised across a 2022 $33M Series B led by Section 32 and Sanofi Ventures, a 2024 $14M strategic round led by M Ventures (Merck KGaA), and earlier rounds. Strategic pharma CVCs (Sanofi Ventures, M Ventures, Debiopharm) sit alongside financial investors (Section 32, Vertex Ventures, Grove Ventures), and the investor mix is directly leveraged through partnership channels into Bio-Techne, Sirona Dx, and academic translational programs such as the University of Glasgow SPARC colorectal cancer initiative. Headcount is reported in the 51-100 range.

Short descriptiontext

Nucleai is a spatial biology company that has built an AI-powered multimodal platform for analyzing tissue biopsies to discover spatial biomarkers and predict patient response to oncology therapies, primarily serving top-tier biopharmaceutical companies, life-science tools partners, and academic research institutions globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biomarker analysis, AI drug development, digital pathology platform, multiplex immunofluorescence analytics, companion diagnostics AI
Industry2 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services51821
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Spatial Biology AI Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise SaaS / Platform Licensing
TypeSubscription Recurring
Description

Nucleai's "Solution" is provided as an image analysis and biomarker discovery platform delivered via a cloud application (app.nucleai.cloud) under customer agreements. The Nucleai Platform and its Results are governed by Customer Agreements that govern usage rights, indicating recurring enterprise licensing/subscription revenue from biopharma customers.

nucleai.ai
2Strategic Co-Development / Custom Project Engagements
TypeProfessional Services
Description

Project-based, milestone-driven revenue from joint spatial proteomics and biomarker discovery programs with biopharma, CROs (e.g., Sirona Dx integrated end-to-end offering), and academic partners (e.g., University of Glasgow SPARC). May combine licensing with services for assay design, validation, and bespoke AI analysis.

nucleai.ai
3Research Use Only (RUO) Image Analysis Tooling
TypeLicensing Royalties
Description

The Solution is explicitly designated "for research use only (RUO) and not intended for diagnostic purposes" per User Terms — revenue currently derived from RUO analytical workflows, with stated ambition to transition into clinical diagnostic products (companion diagnostics) over the next 2–5 years per CEO.

nucleai.ai
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Quote-based enterprise agreement (no public price list)
ModelOther
Notes

Pricing is custom; customers contact sales for a demo/quote. Solution is delivered as a SaaS application (app.nucleai.cloud) and governed by individual Customer Agreements.

nucleai.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nucleai provides an AI-powered multimodal spatial biomarker analysis platform delivered as a cloud-based application (app.nucleai.cloud) that ingests H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics images alongside clinical data to identify predictive spatial biomarkers, automate biomarker scoring, and predict response to therapy. The platform is licensed to biopharma, CRO, and academic customers under enterprise Customer Agreements and is paired with strategic co-development engagements, an automated deep learning model for high-plex normalization, and an AI-powered spatial proteomics agent for report generation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Prediction accuracy improved from ~30% to 70–80% by incorporating spatial biology context into patient response prediction
+3 more records
Product overview1 text field

Nucleai offers a single unified AI-driven spatial biomarker analysis platform (a "multimodal spatial operating system") with an add-on deep-learning model, an AI-powered spatial proteomics agent, an Analysis Studio viewer, and an OD-based quantitative biomarker scoring solution. The core platform powers six solution areas: Biomarker Discovery & Validation, Biomarker Scoring, Genomic Biomarker Screening, Mechanism of Action (MoA), Data Enrichment, and Companion Diagnostics, with companion-diagnostic deployments also enabled through the Sirona Dx partnership. The Analysis Studio is the interactive viewer layered on top of the platform, the deep-learning model automates spatial proteomics interpretation, the AI-powered spatial proteomics agent uses LLMs to surface insights and generate reports, and the OD-based quantitative biomarker scoring module standardizes quantification within the platform.

Product and service5 records
1Nucleai Spatial Biomarker Analysis Platform
CategoryCore Platform / Spatial Biology SaaS
Description

AI-driven multimodal spatial operating system that ingests high-plex imaging, histopathology, and clinical outcome data to support spatial biomarker discovery, scoring, mechanism-of-action studies, and prediction of therapy response for biopharma, academic, and CRO customers.

2Deep Learning Model for Spatial Proteomics
CategoryAdd-on / Foundation Model
Description

First-of-its-kind deep learning model that automates normalization of high-plex mIF imaging data and biomarker quantification, ~20x faster than manual methods, running in minutes and scaling across hundreds of samples.

3AI-Powered Spatial Proteomics Agent
CategoryAdd-on / AI Agent
Description

LLM-powered agent that surfaces insights and auto-generates narrative reports from spatial proteomics datasets, enabling researchers to explore complex spatial data without specialized support.

4Analysis Studio
CategoryAdd-on / Viewer
Description

Interactive viewer that lets users navigate cell types, marker expression, and spatial neighborhoods across tissue regions, enabling exploration of complex spatial datasets without specialized support.

5OD-based Quantitative Biomarker Scoring
CategoryAdd-on / Scoring Module
Description

Optical density-based quantitative biomarker scoring that solves challenges of manual visual IHC scoring by pathologists, enabling high-sensitivity detection of low-level biomarker expression and subcellular (membrane vs. cytoplasm) protein expression.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagship Cro Co-Delivery Partnership For End-To-End Spatial Proteomics SolutionTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Strategic partnership to deliver a fully integrated, scalable spatial proteomics solution for pharmaceutical and biotechnology companies. Sirona Dx (GCLP- and CLIA-accredited Technical CRO) leads assay design, development, and validation; Nucleai delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Joint offering covers oncology, immunology, and neuroscience applications including biomarker discovery/validation, patient stratification, MoA studies, and clinical trial biomarker programs.

Strategic tierFlagship Academic Partnership For Global Precision Medicine Network LaunchTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Collaboration to identify and validate predictive biomarkers for colorectal cancer (CRC) and advanced polyp incidence, leveraging the INCISE study cohort. Combines Glasgow's SPARC spatial-omics capability with Nucleai's multimodal spatial pipeline integrating mIF, IHC, H&E, and clinical data. The project will analyze tissue architecture, cell-to-cell interactions, and molecular signaling to enable clinically validated precision diagnostic products for risk prediction and surveillance. Quote: "Deep phenotyping of pathology specimens using spatial omics technologies has the potential to revolutionize our understanding of disease mechanisms and progression." (Prof. Nigel Jamieson).

Strategic tierFlagship Life-Science Tools Integration Partner Since 2022TypeTechnology or IntegrationAnnounced on2025-11-04
Description

Co-developed high-plex mIF + AI multimodal biomarker analysis workflow. The SECOMBIT clinical trial study used Bio-Techne's COMET platform with a 28-plex mIF panel and Nucleai's multimodal spatial operating system to profile 42 pre-treatment metastatic melanoma biopsies across three ICB treatment arms. Joint SITC 2024 and 2025 presentations; co-marketed at AACR/ASCO/SITC booths.

4University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale (Prof. Paolo Ascierto)
Strategic tierKey Clinical Research Collaborator For Secombit Trial And Melanoma ProgramTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Research collaboration on the SECOMBIT clinical trial, integrating a 28-plex mIF IO panel with Nucleai's multimodal AI biomarker analysis to profile 42 pre-treatment biopsies from metastatic melanoma patients. Co-presented at SITC 2024/2025 and ASCO 2025 (Poster #247328).

nucleai.ai
Strategic tierKey Research Collaboration For Translational Nsclc InsightsTypeStrategic or Co-development PartnerAnnounced on2024-11-05
Description

Research collaboration profiling metabolic states of tumor and immune cells in NSCLC patients treated with checkpoint inhibitors. Nucleai's AI biomarker platform and scientific expertise were used to rapidly analyze spatial data from multiple patient cohorts and extract clinically relevant insights, published in Nature Communications (2026). SITC 2024 abstract #109.

Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

8Fox Chase Cancer Center
Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

nucleai.ai
Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

12Rambam Health Care Campus (Israel)
Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

nucleai.ai
13Clalit Health Services (Israel)
Strategic tierData/Institutional Partner (Clinical Research Site)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.

nucleai.ai
Strategic tierStrategic Investor And Data/Institutional Partner (Dual Role — Also Financial)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as both a Data/Institutional Partner and Investor. Debiopharm Innovation Fund holds a board seat (Tom Gibbs) and Debiopharm has a board observer (Antoine Attinger).

15Merck KGaA / EMD (EMD Serono)
Strategic tierStrategic Pharma Partner And Investor (Dual Role — Also Financial Via M Ventures)TypeStrategic or Co-development Partner
Description

Listed on Nucleai's homepage as a Data/Institutional Partner. Connected to M Ventures (the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany) which led the $14M investment in April 2024. Noga Yerushalmi, PhD, Investment Director at M Ventures, sits on Nucleai's board.

nucleai.ai
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based AI pathology company offering a digital pathology platform and biomarker discovery services for biopharma, with a comparable product-market fit in AI-driven tissue analysis for pharma R&D and clinical trial support.

TypeDirect peer
Description

AI-for-drug-discovery company that applies multimodal machine learning to patient data (including pathology) for biopharma, with overlapping use cases in biomarker discovery, patient stratification, and clinical trial optimization.

TypeDirect peer
Description

Spatial biology company offering multiplexed immunofluorescence and RNA-ISH platforms (PhenoCycler, PhenoImager) with its own AI-driven tissue analysis and biopharma biomarker discovery services, directly competitive in spatial biomarker workflows.

TypeDirect peer
Description

South Korea-based AI pathology company (Lunit SCOPE) with biopharma partnerships for biomarker analysis and predictive biomarker development in oncology, with overlapping customers and use cases to Nucleai.

TypeBroad incumbent
Description

Dominant spatial transcriptomics and single-cell platform company (Visium, Xenium) that is increasingly building downstream AI analytics; a broad incumbent whose customers overlap with Nucleai's biopharma and academic end markets.

TypeDirect peer
Description

AI-powered digital pathology platform company serving biopharma and clinical diagnostics with H&E-based AI biomarker solutions; competes for pharma R&D pathology budgets with a more pathology-software-centric offering.

7Aignostics
TypeEmerging player
Description

Berlin-based AI pathology company spun out of Charité, focused on multimodal AI-driven biomarker discovery for biopharma; competes for European pharma and academic spatial biomarker engagements.

TypeDirect peer
Description

Israel-based AI pathology company with a strong H&E-based cancer detection platform that also serves biopharma; competes for clinical trial pathology workflows and shares Nucleai's Israel-based R&D ecosystem.

TypeEmerging player
Description

Norway-based AI pathology company developing AI biomarkers for cancer prognosis and treatment prediction; comparable in addressing the AI-biomarker-for-therapy-response use case for biopharma partners.

TypeBroad incumbent
Description

Acquired NanoString's spatial biology assets in 2024, including the GeoMx and CosMx spatial platforms, and is a large incumbent competing across multiplex spatial biology workflows that overlap with Nucleai's biopharma end market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleai

Spatial Biology AI Softwarenucleai.ai

Nucleai is a spatial biology company that has built an AI-powered multimodal platform for analyzing tissue biopsies to discover spatial biomarkers and predict patient response to oncology therapies, primarily serving top-tier biopharmaceutical companies, life-science tools partners, and academic research institutions globally.

What Nucleai does

Nucleai is a spatial biology company founded in 2017/2018 in Israel by Avi Veidman, applying geospatial and satellite-imagery AI techniques to the analysis of tissue biopsies. The company has built an AI-powered multimodal spatial biology platform that ingests H&E, IHC, multiplex immunofluorescence (mIF), and spatial transcriptomics images to perform spatial biomarker discovery, scoring, and prediction of therapy response. The platform is delivered as a cloud application (app.nucleai.cloud) and includes specialized deep-learning models — including a high-plex imaging normalization model with reported 20x speedup and an LLM-based spatial proteomics agent that generates automated reports — supported by peer-reviewed publications in Nature Communications and Modern Pathology.

Nucleai's customer base is concentrated in the top tier of biopharmaceutical companies, with stated engagement with 20+ pharma customers including Gilead, Amgen, and other Top 20 Biopharma. Revenue is generated through three primary streams: enterprise SaaS and platform licensing to biopharma, strategic co-development arrangements with CROs (Sirona Dx) and life-science tools companies (Bio-Techne/Lunaphore), and research-use-only image analysis services for academic and translational research. The company operates a dual-headquarters structure with offices in Tel Aviv, Israel (R&D and engineering) and Chicago, Illinois (US commercial operations).

Total disclosed equity funding is approximately $60M, raised across a 2022 $33M Series B led by Section 32 and Sanofi Ventures, a 2024 $14M strategic round led by M Ventures (Merck KGaA), and earlier rounds. Strategic pharma CVCs (Sanofi Ventures, M Ventures, Debiopharm) sit alongside financial investors (Section 32, Vertex Ventures, Grove Ventures), and the investor mix is directly leveraged through partnership channels into Bio-Techne, Sirona Dx, and academic translational programs such as the University of Glasgow SPARC colorectal cancer initiative. Headcount is reported in the 51-100 range.

Nucleai firmographics

Firmographics
Name
Nucleai
Legal name
Nucleai Ltd.
Website
https://nucleai.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Nucleai is a spatial biology company that has built an AI-powered multimodal platform for analyzing tissue biopsies to discover spatial biomarkers and predict patient response to oncology therapies, primarily serving top-tier biopharmaceutical companies, life-science tools partners, and academic research institutions globally.
Ownership category
akta.pro rank

Nucleai industry classification

Industry
Product category
Spatial Biology AI Software
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Spatial biomarker analysis
  • AI drug development
  • Digital pathology platform
  • Multiplex immunofluorescence analytics
  • Companion diagnostics AI

Where Nucleai is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nucleai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Enterprise SaaS / Platform Licensing: Nucleai's "Solution" is provided as an image analysis and biomarker discovery platform delivered via a cloud application (app.nucleai.cloud) under customer agreements. The Nucleai Platform and its Results are governed by Customer Agreements that govern usage rights, indicating recurring enterprise licensing/subscription revenue from biopharma customers.
  2. Strategic Co-Development / Custom Project Engagements: Project-based, milestone-driven revenue from joint spatial proteomics and biomarker discovery programs with biopharma, CROs (e.g., Sirona Dx integrated end-to-end offering), and academic partners (e.g., University of Glasgow SPARC). May combine licensing with services for assay design, validation, and bespoke AI analysis.
  3. Research Use Only (RUO) Image Analysis Tooling: The Solution is explicitly designated "for research use only (RUO) and not intended for diagnostic purposes" per User Terms — revenue currently derived from RUO analytical workflows, with stated ambition to transition into clinical diagnostic products (companion diagnostics) over the next 2–5 years per CEO.

Pricing tiers

ModelBillingPrice
Other—Quote-based enterprise agreement (no public price list)

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Nucleai product offering

Product offering

Core offering

Nucleai provides an AI-powered multimodal spatial biomarker analysis platform delivered as a cloud-based application (app.nucleai.cloud) that ingests H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics images alongside clinical data to identify predictive spatial biomarkers, automate biomarker scoring, and predict response to therapy. The platform is licensed to biopharma, CRO, and academic customers under enterprise Customer Agreements and is paired with strategic co-development engagements, an automated deep learning model for high-plex normalization, and an AI-powered spatial proteomics agent for report generation.

Product overview

Nucleai offers a single unified AI-driven spatial biomarker analysis platform (a "multimodal spatial operating system") with an add-on deep-learning model, an AI-powered spatial proteomics agent, an Analysis Studio viewer, and an OD-based quantitative biomarker scoring solution. The core platform powers six solution areas: Biomarker Discovery & Validation, Biomarker Scoring, Genomic Biomarker Screening, Mechanism of Action (MoA), Data Enrichment, and Companion Diagnostics, with companion-diagnostic deployments also enabled through the Sirona Dx partnership. The Analysis Studio is the interactive viewer layered on top of the platform, the deep-learning model automates spatial proteomics interpretation, the AI-powered spatial proteomics agent uses LLMs to surface insights and generate reports, and the OD-based quantitative biomarker scoring module standardizes quantification within the platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nucleai Spatial Biomarker Analysis Platform AI-driven multimodal spatial operating system that ingests high-plex imaging, histopathology, and clinical outcome data to support spatial biomarker discovery, scoring, mechanism-of-action studies, and prediction of therapy response for biopharma, academic, and CRO customers.
  • Deep Learning Model for Spatial Proteomics First-of-its-kind deep learning model that automates normalization of high-plex mIF imaging data and biomarker quantification, ~20x faster than manual methods, running in minutes and scaling across hundreds of samples.
  • AI-Powered Spatial Proteomics Agent LLM-powered agent that surfaces insights and auto-generates narrative reports from spatial proteomics datasets, enabling researchers to explore complex spatial data without specialized support.
  • Analysis Studio Interactive viewer that lets users navigate cell types, marker expression, and spatial neighborhoods across tissue regions, enabling exploration of complex spatial datasets without specialized support.
  • OD-based Quantitative Biomarker Scoring Optical density-based quantitative biomarker scoring that solves challenges of manual visual IHC scoring by pathologists, enabling high-sensitivity detection of low-level biomarker expression and subcellular (membrane vs. cytoplasm) protein expression.

Quantifiable outcome

  • Prediction accuracy improved from ~30% to 70–80% by incorporating spatial biology context into patient response prediction
  • +3 more outcomes

Companies that use Nucleai

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Nucleai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability11 records

Feature6 records

Nucleai partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship cro co-delivery partnership for end-to-end spatial proteomics solution, flagship academic partnership for global precision medicine network launch, flagship life-science tools integration partner since 2022, key clinical research collaborator for secombit trial and melanoma program, key research collaboration for translational nsclc insights, data/institutional partner (clinical research site), strategic investor and data/institutional partner (dual role — also financial) and strategic pharma partner and investor (dual role — also financial via m ventures).

  • Sirona Dxflagship cro co-delivery partnership for end-to-end spatial proteomics solutionStrategic or Co-development Partner · 15 April 2026Strategic partnership to deliver a fully integrated, scalable spatial proteomics solution for pharmaceutical and biotechnology companies. Sirona Dx (GCLP- and CLIA-accredited Technical CRO) leads assay design, development, and validation; Nucleai delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Joint offering covers oncology, immunology, and neuroscience applications including biomarker discovery/validation, patient stratification, MoA studies, and clinical trial biomarker programs.
  • University of Glasgow (SPARC — Spatial Pathology Analytics for Research and Clinical Integration)flagship academic partnership for global precision medicine network launchStrategic or Co-development Partner · 12 November 2025Collaboration to identify and validate predictive biomarkers for colorectal cancer (CRC) and advanced polyp incidence, leveraging the INCISE study cohort. Combines Glasgow's SPARC spatial-omics capability with Nucleai's multimodal spatial pipeline integrating mIF, IHC, H&E, and clinical data. The project will analyze tissue architecture, cell-to-cell interactions, and molecular signaling to enable clinically validated precision diagnostic products for risk prediction and surveillance. Quote: "Deep phenotyping of pathology specimens using spatial omics technologies has the potential to revolutionize our understanding of disease mechanisms and progression." (Prof. Nigel Jamieson).
  • Bio-Techne Corporation (NASDAQ: TECH) — including Lunaphore (COMET, SPYRE, ProximityScope)flagship life-science tools integration partner since 2022Technology or Integration · 4 November 2025Co-developed high-plex mIF + AI multimodal biomarker analysis workflow. The SECOMBIT clinical trial study used Bio-Techne's COMET platform with a 28-plex mIF panel and Nucleai's multimodal spatial operating system to profile 42 pre-treatment metastatic melanoma biopsies across three ICB treatment arms. Joint SITC 2024 and 2025 presentations; co-marketed at AACR/ASCO/SITC booths.
  • University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale (Prof. Paolo Ascierto)key clinical research collaborator for secombit trial and melanoma programStrategic or Co-development Partner · 4 November 2025Research collaboration on the SECOMBIT clinical trial, integrating a 28-plex mIF IO panel with Nucleai's multimodal AI biomarker analysis to profile 42 pre-treatment biopsies from metastatic melanoma patients. Co-presented at SITC 2024/2025 and ASCO 2025 (Poster #247328).
  • University of Queensland (Dr. Arutha Kulasinghe, Frazer Institute) and Yale School of Medicine (Dr. David Rimm)key research collaboration for translational nsclc insightsStrategic or Co-development Partner · 5 November 2024Research collaboration profiling metabolic states of tumor and immune cells in NSCLC patients treated with checkpoint inhibitors. Nucleai's AI biomarker platform and scientific expertise were used to rapidly analyze spatial data from multiple patient cohorts and extract clinically relevant insights, published in Nature Communications (2026). SITC 2024 abstract #109.
  • Mayo Clinicdata/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • University of Pennsylvania (UPenn)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Fox Chase Cancer Centerdata/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Thomas Jefferson University (Jefferson)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Sheba Medical Center (Israel)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Kaplan Medical Center (Israel)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Rambam Health Care Campus (Israel)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Clalit Health Services (Israel)data/institutional partner (clinical research site)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
  • Debiopharm (Innovation Fund)strategic investor and data/institutional partner (dual role — also financial)Strategic or Co-development PartnerListed on Nucleai's homepage as both a Data/Institutional Partner and Investor. Debiopharm Innovation Fund holds a board seat (Tom Gibbs) and Debiopharm has a board observer (Antoine Attinger).
  • Merck KGaA / EMD (EMD Serono)strategic pharma partner and investor (dual role — also financial via m ventures)Strategic or Co-development PartnerListed on Nucleai's homepage as a Data/Institutional Partner. Connected to M Ventures (the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany) which led the $14M investment in April 2024. Noga Yerushalmi, PhD, Investment Director at M Ventures, sits on Nucleai's board.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Nucleai competitors and assessment

Company assessment

Direct peers

  • PathAI: Boston-based AI pathology company offering a digital pathology platform and biomarker discovery services for biopharma, with a comparable product-market fit in AI-driven tissue analysis for pharma R&D and clinical trial support.
  • Owkin: AI-for-drug-discovery company that applies multimodal machine learning to patient data (including pathology) for biopharma, with overlapping use cases in biomarker discovery, patient stratification, and clinical trial optimization.
  • Akoya Biosciences: Spatial biology company offering multiplexed immunofluorescence and RNA-ISH platforms (PhenoCycler, PhenoImager) with its own AI-driven tissue analysis and biopharma biomarker discovery services, directly competitive in spatial biomarker workflows.
  • Lunit: South Korea-based AI pathology company (Lunit SCOPE) with biopharma partnerships for biomarker analysis and predictive biomarker development in oncology, with overlapping customers and use cases to Nucleai.
  • Proscia: AI-powered digital pathology platform company serving biopharma and clinical diagnostics with H&E-based AI biomarker solutions; competes for pharma R&D pathology budgets with a more pathology-software-centric offering.
  • Ibex Medical Analytics: Israel-based AI pathology company with a strong H&E-based cancer detection platform that also serves biopharma; competes for clinical trial pathology workflows and shares Nucleai's Israel-based R&D ecosystem.

Broad incumbents

  • 10x Genomics: Dominant spatial transcriptomics and single-cell platform company (Visium, Xenium) that is increasingly building downstream AI analytics; a broad incumbent whose customers overlap with Nucleai's biopharma and academic end markets.
  • Bruker (NanoString spatial biology): Acquired NanoString's spatial biology assets in 2024, including the GeoMx and CosMx spatial platforms, and is a large incumbent competing across multiplex spatial biology workflows that overlap with Nucleai's biopharma end market.

Emerging players

  • Aignostics: Berlin-based AI pathology company spun out of Charité, focused on multimodal AI-driven biomarker discovery for biopharma; competes for European pharma and academic spatial biomarker engagements.
  • DoMore Diagnostics: Norway-based AI pathology company developing AI biomarkers for cancer prognosis and treatment prediction; comparable in addressing the AI-biomarker-for-therapy-response use case for biopharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nucleai social profiles

Digital presence

Nucleai compliance and trust

Trust signal

Compliance2 records

Nucleai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleai leadership team

Management profile

Number of profiles

Profiles15 records

Nucleai subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nucleai funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleai M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleai

What does Nucleai do?

Nucleai provides an AI-powered multimodal spatial biomarker analysis platform delivered as a cloud-based application (app.nucleai.cloud) that ingests H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics images alongside clinical data to identify predictive spatial biomarkers, automate biomarker scoring, and predict response to therapy. The platform is licensed to biopharma, CRO, and academic customers under enterprise Customer Agreements and is paired with strategic co-development engagements, an automated deep learning model for high-plex normalization, and an AI-powered spatial proteomics agent for report generation.

Is Nucleai a public or private company?

Nucleai is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nucleai founded?

Nucleai was founded in 2018. It employs 51 to 100 people.

Where is Nucleai based?

Nucleai is headquartered in Chicago, United States, in the North America region.

How does Nucleai make money?

Three revenue lines are on record. Enterprise SaaS / Platform Licensing is the primary driver. The others are strategic Co-Development / Custom Project Engagements and research Use Only (RUO) Image Analysis Tooling.

Who are Nucleai's main competitors?

Direct peers on record are PathAI, Owkin, Akoya Biosciences, Lunit, Proscia and Ibex Medical Analytics. Broad incumbents are 10x Genomics and Bruker (NanoString spatial biology). Emerging players are Aignostics and DoMore Diagnostics.

Does Nucleai have an API?

No public API is recorded for Nucleai.

What industry is Nucleai in?

Nucleai's product category is Spatial Biology AI Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 51821 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestGilead's oncology future depends on molecules, not algorithmsGilead Sciences announced a collaboration with Nucleai to utilize AI for tissue analytics in its antibody-drug-conjugate oncology programs. This strategic move comes as Gilead attempts to diversify its revenue stream from HIV drugs following significant financial losses from recent acquisitions totaling over $32 billion. Analysts caution that the partnership offers no immediate regulatory or commercial impact, emphasizing that Gilead's success depends on clinical trial outcomes rather than algorithmic tools.Simply Wall StIs Gilead (GILD) Using AI Tissue Analytics To Quietly Redefine Its Oncology Edge?Gilead Sciences has entered a translational research collaboration with Nucleai to utilize AI-driven tissue analytics for its global antibody-drug conjugate clinical development programs in oncology. This partnership aims to standardize biomarker assessment and generate insights that support the precision oncology strategy, particularly for assets like Trodelvy. The announcement is viewed as a modest step in Gilead's diversification efforts away from its mature HIV business.BioPharm InternationalNucleai and Gilead Expand AI-Powered Tissue Analytics Collaboration to Support ADC DevelopmentNucleai announced an expansion of its AI-powered tissue analytics collaboration with Gilead Sciences to support the development of antibody-drug conjugates (ADCs). Nucleai analyzed clinical datasets to generate biological insights and candidate spatial biomarkers, aiming to improve patient selection and therapeutic efficacy prediction beyond simple target expression. The companies did not disclose specific timelines for publishing findings from this ongoing translational research partnership.DrugdiscoverytrendsGilead and Nucleai probe why target-positive tumors can still resist ADCsGilead Sciences and Nucleai are collaborating to investigate why tumors that appear target-positive via standard pathology tests can still resist antibody-drug conjugate (ADC) therapies. The partnership involves analyzing clinical trial datasets using AI-driven spatial biology to identify more predictive biomarkers than conventional immunohistochemistry. This effort aims to resolve discrepancies between tissue assay results and actual drug engagement within the tumor microenvironment.SahmcapitalWill Gilead’s AI-Driven ADC Research with Nucleai Refine Its Oncology Strategy and Valuation Story (GILD)?Nucleai announced a translational research collaboration with Gilead Sciences to utilize AI-powered tissue analytics for supporting antibody-drug conjugate clinical development programs. This partnership aims to generate candidate spatial biomarkers across multiple oncology indications, aligning with Gilead's strategic pivot toward precision oncology despite current financial volatility.BioSpaceNucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC CollaborationNucleai has announced an ongoing translational research collaboration with Gilead Sciences to support the pharmaceutical company's global antibody-drug conjugate clinical development programs. This collaboration focuses on utilizing AI-driven tissue analytics to enhance biomarker discovery and precision oncology research. The partnership illustrates the growing emphasis on integrating tissue biology with clinical outcomes in drug development.Business Wire BlogNucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC CollaborationNucleai announced an ongoing collaboration with Gilead Sciences to support its global ADC clinical development programs through AI-powered tissue analytics. The collaboration has analyzed a large dataset of clinical images across multiple oncology indications to generate biological insights and candidate biomarkers.MorningstarNucleai Expands its Strategic Partnership with University of Glasgow to Advance Access to Its Multimodal Tissue Intelligence AI PlatformNucleai expanded access to its multimodal tissue intelligence AI platform through a partnership with the University of Glasgow's SPARC Lab. The collaboration enables multiplex image analysis for academic research, compressing tissue-to-insight timelines from months to weeks. Nucleai is exploring further collaborations with institutions using unique spatial datasets.Business Wire BlogNucleai Expands its Strategic Partnership with University of Glasgow to Advance Access to Its Multimodal Tissue Intelligence AI PlatformNucleai announced an expanded strategic partnership with the University of Glasgow's SPARC Lab to provide academic and translational researchers access to its multimodal spatial analytics platform for multiplex immunofluorescence imaging data analysis. The collaboration enables the platform to analyze complex imaging data and compress tissue-to-insight timelines from months to weeks, addressing a critical bottleneck in spatial biology research. Nucleai indicated this partnership is the first step in a broader effort to expand platform access to academic and translational groups working with spatial proteomics and multimodal tissue data.Pharmaceutical TechnologyNucleai, Sirona Dx to provide new proteomics solution for pharma firmsNucleai and Sirona Dx have formed a partnership to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology companies involved in drug development. The collaboration combines Sirona Dx's expertise in assay design and validation with Nucleai's AI-based spatial analytics to bridge the gap between data generation and actionable biological insights. This unified workflow aims to improve biomarker decisions and clinical success rates in fields such as immunology, neuroscience, and oncology.